Skip to Content
Merck
  • X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation.

X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation.

Clinical immunology (Orlando, Fla.) (2008-09-09)
Eric M Lewis, Manav Singla, Susan Sergeant, Patrick P Koty, Linda C McPhail
ABSTRACT

Chronic granulomatous disease (CGD) is characterized by defects in the superoxide producing enzyme NADPH oxidase causing phagocytes to improperly clear invading pathogens. Here we report findings of a late presenting 16-year-old female with X-linked CGD. The patient presented with community-acquired pneumonia, but symptoms persisted for 2 weeks during triple antimicrobial coverage. Cultures revealed Aspergillus fumigatus which was resolved through aggressive voriconazole treatment. Neutrophil studies revealed NADPH oxidase activity and flavocytochrome b(558) levels that were 4-8% of controls and suggested carrier status of the mother. We found a null mutation in the CYBB gene (c.252insAG) predicting an aberrant gp91(phox) protein (p.Cys85fsX23) in the heterozygous state. Methylation analysis demonstrated extremely skewed X chromosome inactivation favoring the maternally inherited defective gene. In conclusion, a novel mutation in the CYBB gene and an extremely skewed X-inactivation event resulted in the rare expression of the CGD phenotype in a carrier female.

MATERIALS
Product Number
Brand
Product Description

Avanti
10:0 PA, 1,2-didecanoyl-sn-glycero-3-phosphate (sodium salt), powder
Avanti
10:0 PA, 1,2-didecanoyl-sn-glycero-3-phosphate (sodium salt), chloroform
Sigma-Aldrich
Anti-Rac1 Antibody, clone 23A8, clone 23A8, Upstate®, from mouse